Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents

Novel rhodium, iridium, and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anticancer agents. The complexes show promising cytotoxicities, with the presence, position, and number of halides having a significant effect on the corresponding...

Full description

Saved in:
Bibliographic Details
Published inInorganic chemistry Vol. 53; no. 2; pp. 727 - 736
Main Authors Almodares, Zahra, Lucas, Stephanie J, Crossley, Benjamin D, Basri, Aida M, Pask, Christopher M, Hebden, Andrew J, Phillips, Roger M, McGowan, Patrick C
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 21.01.2014
Subjects
Amides - chemistry
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Cell Hypoxia
HT29 Cells
Humans
Inhibitory Concentration 50
Iridium - chemistry
MCF-7 Cells
Organometallic Compounds - chemical synthesis
Organometallic Compounds - chemistry
Organometallic Compounds - pharmacology
Picolinic Acids - chemistry
Rhodium - chemistry
Ruthenium - chemistry
Online AccessGet full text

Cover

More Information
Summary:Novel rhodium, iridium, and ruthenium half-sandwich complexes containing (N,N)-bound picolinamide ligands have been prepared for use as anticancer agents. The complexes show promising cytotoxicities, with the presence, position, and number of halides having a significant effect on the corresponding IC50 values. One ruthenium complex was found to be more cytotoxic than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively, and it remains active with MCF-7 cells even under hypoxic conditions, making it a promising candidate for in vivo studies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0020-1669
1520-510X
1520-510X
DOI:10.1021/ic401529u